PDCD1 and neoplasm: To substantiate these findings, we employed a subcutaneous tumor model using a mouse ESCC cell line (mEC25) and treated the mice with anti-PD-1 monotherapy, anti-IL-6 monotherapy, or a combination of both (Fig. 4j).